<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acce/7471018/7375dcbd1d8f/TCA-11-2704-g002.jpg"/> </div> <div class="text-side"> <h1>Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma.</h1> <p>Pathology and amplification refractory mutation system‐polymerase chain reaction (ARMS‐PCR). (a) At the time of diagnosis. Hematoxylin and eosin (HE) staining showed neoplastic cells with morphological characteristics of non‐small cell lung cancer (NSCLC). (b–e) At the time of diagnosis. (b) Immunohistochemistry revealed diffuse expression of P40; (c) CK (5/6); (d) negative expression of TTF‐1; and (e) Napsin A, which led to the diagnosis of lung squamous cell carcinoma. (f) At the time of surgery. HE staining showed a necrotic area of former cancer tissue, with no residual viable cancer cells. (g) At the time of diagnosis. ARMS‐PCR showed coexistence of epidermal growth factor receptor (EGFR) exon 19Del and T790M (magnification: 200x; scale bar: 50 μm).</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32667739/" target="_blank">32667739</a></p><p>Type: Premalignant/Malignant, Category: Keratinocytic</p>
</div> </div></div></body></html>